|  |  |
| --- | --- |
| **Dr. Constantinos C. Tellis**  Laboratory Teaching Staff of Biochemistry and Clinical Chemistry  Section of Organic Chemistry and Biochemistry/  Atherothrombosis Research Centre (ARC)  Department of Chemistry  University of Ioannina  45110 Ioannina – Greece  Office: X3-204γ / Lab.: X3-124  Tel.: +306973381582, +302651008326  Email: ktellis@uoi.gr |  |

|  |  |
| --- | --- |
| **Title** | Doctor in Biochemistry and Clinical Chemistry |
| **Education**  Ph.D. in Chemistry  BSc in Chemistry | Doctoral Degree in Biochemistry of Lipids and Membranes. Title of Thesis: “Biosynthesis of Platelet Activating Factor in protozoan *Tetrahymena pyriformis*”, Section of Organic Chemistry and Biochemistry, Department of Chemistry, University of Ioannina, Greece (1999).  BSc in Chemistry Department of Chemistry, University of Ioannina, Greece (1993). |
| **Research & Professional Appointments** | Coordinator of Biochemistry laboratory exercises, Laboratory of Biological Chemistry, School of Medicine, of elective Research and educational program “Biochemistry” of the University of Ioannina - (1999 – 2002)  Postdoctoral Fellow, Research Associate, at the Atherothrombosis Research Center (ARC), of the Network of Research Supporting Laboratories (NRSL) of the University of Ioannina, Greece (2002 –until today) |
| **Course Lectures:**  Lectures in the Undergraduate and postgraduate Courses of the Department of Chemistry, UOI  -Until today | Undergraguate Courses:  -Lectures and experimental exercises in the course “Biochemistry Laboratory”  -Lectures in the course “Introduction of Clinical Biochemistry”  -Lectures experimental exercises in the course “Laboratory of Clinical Chemistry”  - Lectures in the course “Clinical Chemistry”  -Lectures and experimental exercises in the course “Advanced Laboratory of Biochemistry”  --Supervisor of Under-graduate Theses (Literary or Experimental)  Postgraduate Courses:  -Lectures in the course "Classical and emerging biomarkers of chronic diseases" of Interdepartmental Postgraduate Program "Medical Chemistry" of the UOI  -Lectures in the course "Advanced Biochemistry - Current Topics in Biochemistry"  -Lectures and experimental exercises in the course “Laboratory of Biochemistry Ι and II” of Postgraduate Program of Department of Chemistry UOI  -Supervisor of post-graduate thesis of above postgraduate programs |
| **Scientific Interests** | Biochemistry, Clinical Chemistry, Lipid and Lipoprotein Biochemistry, Inflammation, Immunochemistry, Pathophysiology of Atherosclerosis and Atherothrombosis. Investigation of the underlying mechanisms of atherothrombosis such as: the role of platelets, oxidized lipoproteins and inflammation in the development, progression of atherosclerotic plaque, the biochemical characteristics and biological actions of native or oxidized forms of lipoprotein in patients with various types of dyslipidemias, cardiovascular diseases and chronic kidney disease etc. |
| **Supervision of under-graduate theses**  Department of Chemistry, UOI  2019-2024 | Supervision of several postgraduate theses with successful completion within the framework of the Under-graduate Study Program of the department of Chmeistry of UOI such as:  -Artemis Oikonomou (2019) “The role of HDL in atherosclerosis and cardiovascular disease. Recent Data.”  - Antonis -Paris Karydakis (2019) “The role of Vitamin D in the pathophysiology of atherosclerosis and cardiovascular disease. Recent data  -Solon Sialou (2020) The role of lipoprotein lipase in atherosclerosis and cardiovascular disease  - Eirene Kazakou (2021) “Peroxisome proliferator-activated receptor (PPARs) and their role in atherosclerosis and cardiovascular disease”  - Chrisanthi Petrollari (2021) “Natural compounds and extracts as inhibitors of PCSK9 in atherosclerosis and cardiovascular disease”  Ioanna Iordanou (2022) “Hepatic LXR receptors and their role in atherosclerosis and cardiovascular disease”  -Michaela Vassiliou (2022)“The role of Angiopoitein-like 3 in lipoprotein metabolism and atherosclerosis”  -Raphaela Kosta (2022) “The role of ANGPTL4 in Lipoprotein metabolism and Atherosclerosis”  -Eleni Konstatnopoulou (2022)“MicroRNAs and Cardiovascular Disease”  -Eleni-Maria Zerma (2022)“The pathophysiological role of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) in the brain”  -Anastasia Avella (2023) “Βιοδείκτες φλεγμονής στην αθηροσκληρωτική καρδιαγγειακή νόσο”  Anna Liagkou (2023) “The role of apoCIII in atherosclerosis and cardiovascular disease"  Georgios Maris (2024) «Trimethylamine N-oxide (TMAO) and its Role in Atherosclerosis and Cardiovascular Disease»  Maria-Eirini Kakou (2024) “Pedraxin 3 (PTX3) as a novel biomarker of atherosclerotic cardiovascular disease (ASCVD)” |
| **Supervision of postgraduate theses**  Department of Chemistry, UOI  2019-2024 | Supervision of two postgraduate theses with successful completion within the framework of the Interdepartmental Postgraduate Study Program “Medical Chemistry” of the University of Ioannina  1. Maria Tournoglou (2014) “The role of PCSK9 in the activation of endothelial cells HUVECs, and peripheral blood monocytes by modified forms of lipoproteins”  2. Georgios Tatsis (2015) ”The role of Lp(a) in the quality and functionality characteristics of HDL” |
| **Participation in a three-member examination committee for postgraduate theses**  Department of Chemistry, UOI  2019-2024 | Participation in a three-member examination committee for several postgraduate theses with successful completion within the framework of the Interdepartmental Postgraduate Study Program “Medical Chemistry” of the U.O.I. such as:  -"Investigation of the antiatherogenic and antithrombotic properties of natural products"  -"In Vitro Investigation of Platelet Influence on HepG2 Liver Cancer Cells", -“Investigation of the effect of *Echinacea E*xtracts and their individual components on Atherosclerosis”  -“Study of the Antiatherogenic and Antiplatelet Efficacy of Red Yeast Rice and Tomato Extract In Vitro",  -"Effect of Antibiotics on Thyroid Hormone Biosynthesis: Investigation of the Mechanism of the Interaction of Tetracycline" |
| **Participation in Research Projects** | Participation in sixteen (16) research projects, including the "COMPETITIVENESS" Programs of the National Strategic Reference Framework (NSRF), the "Research-Create-Innovate" Action as well as in innovation research programs of the Hellenic Research Foundation. |
| **Patents** | One (1) Patent. Hellenic Industrial Property Organization (OBI), Patent certificate registration number: 1010640 |
| **Member of scientific societies:** | Member of scientific societies: a)European Atherosclerosis Society (EAS), b) Hellenic Atherosclerosis Society (HES), c) Greek Society of Free Radicals and Oxidative Stress, d) Hellenic Union of Chemists e) Hellenic Society of Biochemistry and Molecular Biology. Committee members: a) Greek Society of Free Radicals and Oxidative Stress, b) Association of Greek Chemists c) Pathophysiology of Atherosclerosis Hellenic Society of Atherosclerosis. |
| **Reviewer in scientific Journals:** | Analytical chemistry, Expert Opinion On Therapeutic Patents, Cardiovascular Diabetology, BMC Cardiovascular Disorders, Hellenic Journal of Atherosclerosis, Lipids in Health and Disease. |
| **Editorial Board and**  **Associated Editor:** | Journal Atherosclerosis Prevention and Treatment |
| **Book(s)** | Title: **Clinical Biochemistry – Diagnosis**, KALLIPOS The Initiative of Open Academic Textbooks, accepted for publication |
| **Abstracts in national and international Congresses** | Up to 150 |
| **Metrics** | 1. Scopus: h-index: 19, citation: 1224, 62 articles <https://www.scopus.com/authid/detail.uri?authorId=10043892900> 2. Google Scholar: h-index: 25, citation: 1864, i10-index: 40   https://scholar.google.gr/citations?user=Ccqnr5cAAAAJ&hl=el |
| **Publications** :68 | |
| [1] G V Papamichail , A N Georgiadis , **C C Tellis**, I Rapti, T E Markatseli, V G Xydis, A D Tselepis, A A Drosos, P V Voulgari. [Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled study](https://scholar.google.gr/citations?view_op=view_citation&hl=el&user=Ccqnr5cAAAAJ&cstart=20&pagesize=80&citation_for_view=Ccqnr5cAAAAJ:xtRiw3GOFMkC). Clin Rheumatol. 2024;43(1):481-488  [2] E. Fotou, V. Moulasioti, G A. Papadopoulos, D. Kyriakou,M-E. Boti, V. Moussis, M. Papadami, **C. Tellis**, A. Patsias, I. Sarrigeorgiou, A. Theodoridis, P. Lymberi, V. Tsiouris, V. Tsikaris, D. Tsoukatos. [Effect of farming system type on broilers’ antioxidant status, performance, and carcass traits: an industrial-scale production study](https://scholar.google.gr/citations?view_op=view_citation&hl=el&user=Ccqnr5cAAAAJ&cstart=20&pagesize=80&citation_for_view=Ccqnr5cAAAAJ:dshw04ExmUIC) Sustainability 2024, 16 (11), 4782  [3] E Fotou, V Moulasioti, D Kyriakou, ME Boti, V Moussis, M Papadami, **C Tellis**, A Patsias, I Sarrigeorgiou, G A. Papadopoulos, P Lymberi, V Tsiouris, V Tsikaris & DTsoukatos Effect of dietary supplementation with oregano oil premix on the antioxidant status, performance, and meat quality in slow-growth broiler chickens Italian Journal of Animal Science 23 (1), 1741-1751  [4] A. Papanikolaou, G Anastasiou, F Barkas, **C Tellis**; K Zikopoulos, E Liberopoulos. Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization Cardiovasc. Dev. Dis. **2024**, 11, 25. https://doi.org/10.3390/jcdd11010025  [5] **C. Tellis**, I. Sarrigeorgiou, G. Tsinti, A. Patsias, E. Fotou, V. Moulasioti, D. Kyriakou, M. Papadami, V. Moussis, M.E. Boti, V. Tsiouris, V. Tsikaris, D. Tsoukatos, P. Lymberi, Pasture vs. Coop: Biomarker Insights into Free-Range and Conventional Broilers, Animals 14 (2024). https://doi.org/10.3390/ani14213070.  [6] I.K. Koutsaliaris, D. Pantazi, A.N. Tsouka, O. Argyropoulou, **C.C. Tellis**, A.D. Tselepis, Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro, Int J Mol Sci 25 (2024). https://doi.org/10.3390/ijms251810136.  [7] I. Sarrigeorgiou, T. Stivarou, G. Tsinti, A. Patsias, E. Fotou, V. Moulasioti, D. Kyriakou, **C. Tellis**, M. Papadami, V. Moussis, V. Tsiouris, V. Tsikaris, D. Tsoukatos, P. Lymberi, Levels of Circulating IgM and IgY Natural Antibodies in Broiler Chicks: Association with Genotype and Farming Systems, Biology (Basel) 12 (2023). <https://doi.org/10.3390/biology12020304>.  [8] I Sarrigeorgiou, G Tsinti, E Fotou, V Moulasioti, D Kyriakou, **C Tellis**, Vassilios Moussis, A Patsias, Th Stivarou, V Tsikaris, V Tsiouris, D Tsoukatos, P Lymberi ELISA Based Quantification of Chicken Specific Troponin-T Peptide in Skeletal Muscle TCA Extracts Conference: 36th European Peptide Symposium 2022; DOI:10.17952/36EPS/36EPS.2022.301  [9] AD Tsiailanis, **CC Tellis**\*, P Papakyriakopoulou, AD Kostagianni, V Gkalpinos, CM Chatzigiannis, N Kostomitsopoulos, G Valsami, AD Tselepis, AG Tzakos. Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen. Molecules **2023**, 28, 2311. <https://doi.org/10.3390/> molecules28052311  [10] H Triantafyllidi, D Benas, **C Tellis**, A Tselepis, E Iliodromitis THE PLASMA HDL-SUBFRACTION PROFILE IN HYPERTENSIVE PATIENTS WITH HIGH HDL-CHOLESTEROL LEVELS Journal of Hypertension, 2023; 41 (Suppl 3), e138-e139  [11] [D Pantazi, **C Tellis,** AD Tselepis Oxidized phospholipids and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) in atherosclerotic cardiovascular disease: An update](https://scholar.google.gr/citations?view_op=view_citation&hl=el&user=Ccqnr5cAAAAJ&citation_for_view=Ccqnr5cAAAAJ:pyW8ca7W8N0C) Biofactors. 2022;48(6):1257-1270. doi: 10.1002/biof.1890  [12] I. Dafnis, A.N. Tsouka, C. Gkolfinopoulou, **C.C. Tellis,** A. Chroni, A.D. Tselepis, PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation, J Lipid Res 63 (2022). https://doi.org/10.1016/j.jlr.2022.100272.  [13] G. Pappas-Gogos, K. Tepelenis, A. Goussia, **C. Tellis,** F. Fousekis, G.K. Glantzounis, K. Vlachos, Plasma VEGF and Leptin Values in Patients With Gastric Intestinal Metaplasia and Metabolic Syndrome, Front Oncol 12 (2022). https://doi.org/10.3389/fonc.2022.905168.  [14] G. Pappas-Gogos, **C.C. Tellis\*,** K. Tepelenis, K. Vlachos, E. Chrysos, A.D. Tselepis, G.K. Glantzounis, Urine 8-Hydroxyguanine (8-OHG) in Patients Undergoing Surgery for Colorectal Cancer, Journal of Investigative Surgery 35 (2022) 591–597. https://doi.org/10.1080/08941939.2021.1904466.  [15] E. Dounousi, **C. Tellis\*,** P. Pavlakou, A. Duni, V. Liakopoulos, P.B. Mark, A. Papagianni, A.D. Tselepis, Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients, Oxid Med Cell Longev 2021 (2021). https://doi.org/10.1155/2021/6677012.  [16] E. Fotou, V. Moulasioti, I. Angelis, V. Tsiouris, A. Patsias, **C. Tellis,** V. Moussis, M.E. Boti, D. Tsoukatos, Influence of dietary olive paste flour on the performance and oxidative stress in chickens raised in field conditions, Journal of the Hellenic Veterinary Medical Society 72 (2021) 3239–3248. <https://doi.org/10.12681/JHVMS.28520>.  [17] T. Tzimas, E. Pappa, S.-F. Ntekouan, M. Georgoulia, L. Angelos, H. **Tellis, C**. Tselepis, A. Milionis, Serum proprotein convertase subtilisin/kexin type 9 levels are increased in patients with transient ischemic attack, J Atherosclerosis Prev Treat. 11 (2020) 5–11. https://www.japt.gr/wp-content/PDF/2020/01\_Tzimas.pdf.  [18] S.E. Makariou, A. Challa, E. Siomou, **C. Tellis,** A. Tselepis, M. Elisaf, E. Liberopoulos, Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity – the effect of vitamin D supplementation: a pilot study, Archives of Medical Science - Atherosclerotic Diseases 5 (2020) 64–71. https://doi.org/10.5114/amsad.2020.95569.  [19] S.E. Makariou, M. Elisaf, A. Challa, **C. Tellis**, A.D. Tselepis, E.N. Liberopoulos, Effect of combined vitamin D administration plus dietary intervention on oxidative stress markers in patients with metabolic syndrome: A pilot randomized study, Clin Nutr ESPEN 29 (2019) 198–202. https://doi.org/10.1016/j.clnesp.2018.10.004.  [20] S.E. Makariou, M. Elisaf, A. Challa, **C.C. Tellis**, A.D. Tselepis, E.N. Liberopoulos, No effect of vitamin D administration plus dietary intervention on emerging cardiovascular risk factors in patients with metabolic syndrome, J Nutr Intermed Metab 16 (2019) 100093. https://doi.org/10.1016/j.jnim.2019.100093.  [21] A.N. Tsouka, **C.C. Tellis\***, A.D. Tselepis, Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives, Curr Pharm Des 24 (2018) 3622–3633. https://doi.org/10.2174/1381612824666181010144823.  [22] Cinoku et al., Autoantibodies to ox-LDL in Sjögren’s syndrome, Clinical and Experimental Rheumatology 2018. 36 (2018) S61–S67.  [23] E. Zvintzou, M. Lhomme, S. Chasapi, S. Filou, V. Theodoropoulos, E. Xapapadaki, A. Kontush, G. Spyroulias, **C.C. Tellis**, A.D. Tselepis, C. Constantinou, K.E. Kypreos, Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity, J Lipid Res 58 (2017) 1869–1883. https://doi.org/10.1194/jlr.M077925.  [24] A.N. Tsouka, **C.C. Tellis\***, A.D. Tselepis, Pharmacology of PCSK9 Inhibitors: Current Status and Future Perspectives, Curr Pharm Des 24 (2018) 3622–3633. https://doi.org/10.2174/1381612824666181010144823.  [25] K. Stamatelopoulos, D. Sibbing, L.S. Rallidis, G. Georgiopoulos, D. Stakos, S. Braun, A. Gatsiou, K. Sopova, C. Kotakos, C. Varounis, **C.C. Tellis**, E. Kastritis, M. Alevizaki, A.D. Tselepis, P. Alexopoulos, C. Laske, T. Keller, A. Kastrati, S. Dimmeler, A.M. Zeiher, K. Stellos, Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease, J Am Coll Cardiol 65 (2015) 904–916. https://doi.org/10.1016/j.jacc.2014.12.035.  [26] E. Theocharidou, **C.C. Tellis**\*, M. Mavroudi, K. Soufleris, T.D. Gossios, O. Giouleme, V.G. Athyros, A.D. Tselepis, A. Karagiannis, Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases, J Crohns Colitis 8 (2014) 936–944. https://doi.org/10.1016/j.crohns.2014.01.016.  [27] T.D. Filippatos, E. Liberopoulos, M. Georgoula, **C. Tellis**, A.D. Tselepis, M. Elisaf, Effects of increased body weight and short-term weight loss on serum PCSK9 levels – a prospective pilot study, Archives of Medical Science - Atherosclerotic Diseases 2 (2017) 46–51. https://doi.org/10.5114/amsad.2017.70502.  [28] G. Pappas-Gogos, **C.C. Tellis\***, G. Trypsianis, K.E. Tsimogiannis, E.C. Tsimoyiannis, C.E. Simopoulos, M. Pitiakoudis, A.D. Tselepis, Oxidative stress in multi-port and single-port cholecystectomy, Journal of Surgical Research 194 (2015) 101–106. https://doi.org/10.1016/j.jss.2014.09.020.  [29] X. Zikou, **C.C. Tellis**,\* K. Rousouli, E. Dounousi, K.C. Siamopoulos, A.D. Tselepis, Differential membrane expression of toll-like receptors and intracellular cytokine induction in peripheral blood monocytes of patients with chronic kidney disease and diabetic nephropathy, Nephron Clin Pract 128 (2014) 399–406. https://doi.org/10.1159/000369815.  [30] A. Kei, **C. Tellis\***, E. Liberopoulos, A. Tselepis, M. Elisaf, Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia, Cardiovasc Ther 32 (2014) 139–146. https://doi.org/10.1111/1755-5922.12072.  [31] C. V. Rizos, E.N. Liberopoulos, **K. Tellis**, J.J. DiNicolantonio, A.D. Tselepis, M.S. Elisaf, Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: Effects on high-density lipoprotein subfractions and associated enzymes, Angiology 66 (2015) 36–42. https://doi.org/10.1177/0003319713512556.  [32] E. Theocharidou, A. Balaska, K. Vogiatzis, **C.C. Tellis**, T.D. Gossios, V.G. Athyros, A.D. Tselepis, A. Karagiannis, Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases, Inflamm Bowel Dis 22 (2016) 2206–2212. https://doi.org/10.1097/MIB.0000000000000873.  [33] G.A. Christou, **C.C. Tellis\***, M.S. Elisaf, A.D. Tselepis, D.N. Kiortsis, The relationship between retinol-binding protein 4 and apolipoprotein b-containing lipoproteins is attenuated in patients with very high serum triglycerides: A pilot study, Hormones 15 (2016) 99–105. https://doi.org/10.14310/horm.2002.1663.  [34] **C. Tellis,** A. Tselepis, Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL, Curr Pharm Des 20 (2014) 6256–6269. https://doi.org/10.2174/1381612820666140622200916.  [35] L.G. Christogiannis, M.S. Kostapanos, **C.C. Tellis**, H.J. Milionis, A.D. Tselepis, M.S. Elisaf, Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension, J Hum Hypertens 27 (2013) 44–50. https://doi.org/10.1038/jhh.2011.108.  [36] E. Moutzouri, E.N. Liberopoulos, **C.C. Tellis,** H.J. Milionis, A.D. Tselepis, M.S. Elisaf, Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia, Atherosclerosis 231 (2013) 8–14. https://doi.org/10.1016/j.atherosclerosis.2013.08.013.  [37] G. Pappas-Gogos, **C. Tellis\*,** K. Lasithiotakis, A.D. Tselepis, K. Tsimogiannis, E. Tsimoyiannis, G. Chalkiadakis, E. Chrysos, Oxidative stress markers in laparoscopic versus open colectomy for cancer: A double-blind randomized study, Surg Endosc 27 (2013) 2357–2365. https://doi.org/10.1007/s00464-013-2788-8.  [38] A. Kei, E. Liberopoulos, **K. Tellis**, M. Rizzo, M. Elisaf, A. Tselepis, Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: A randomized pilot trial, Eur J Clin Invest 43 (2013) 698–707. https://doi.org/10.1111/eci.12095.  [39] C. V. Rizos, E.N. Liberopoulos, **C.C. Tellis,** A.D. Tselepis, M.S. Elisaf, The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F2a levels, Archives of Medical Science 9 (2013) 172–176. https://doi.org/10.5114/aoms.2013.33357.  [40] **C.C. Tellis,** E. Moutzouri, M. Elisaf, R.L. Wolfert, A.D. Tselepis, The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA2, J Lipid Res 54 (2013) 3394–3402. https://doi.org/10.1194/jlr.M041806.  [41] A. Kei, E. Liberopoulos, **C. Tellis**, M. Elisaf, A. Tselepis, Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions, Lipids 48 (2013) 957–965. https://doi.org/10.1007/s11745-013-3826-y.  [42] E. Moutzouri, **C.C. Tellis\*,** K. Rousouli, E.N. Liberopoulos, H.J. Milionis, M.S. Elisaf, A.D. Tselepis, Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide - Induced cytokine production in monocytes of hypercholesterolemic patients, Atherosclerosis 225 (2012) 381–387. https://doi.org/10.1016/j.atherosclerosis.2012.08.037.  [43] A.P. Agouridis, V. Tsimihodimos, T.D. Filippatos, A.A. Dimitriou, **C.C. Tellis**, M.S. Elisaf, D.P. Mikhailidis, A.D. Tselepis, The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia, Expert Opin Pharmacother 12 (2011) 2605–2611. https://doi.org/10.1517/14656566.2011.591383.  [44] L.S. Rallidis, **C.C. Tellis\***, J. Lekakis, I. Rizos, C. Varounis, A. Charalampopoulos, M. Zolindaki, N. Dagres, M. Anastasiou-Nana, A.D. Tselepis, Lipoprotein-associated phospholipase A2 bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: A 3-year follow-up, J Am Coll Cardiol 60 (2012) 2053–2060. https://doi.org/10.1016/j.jacc.2012.06.057.  [45] K.E. Tsimogiannis, **C.C. Tellis**\*, A.D. Tselepis, G.K. Pappas-Gogos, E.C. Tsimoyiannis, G. Basdanis, Toll-like receptors in the inflammatory response during open and laparoscopic colectomy for colorectal cancer, Surg Endosc 26 (2012) 330–336. https://doi.org/10.1007/s00464-011-1871-2.  [46] I.F. Gazi, F.A. Apostolou, E.N. Liberopoulos, T.D. Filippatos, **C.C. Tellis**, M.S. Elisaf, A.D. Tselepis, Leptospirosis is associated with markedly increased triglycerides and small dense low-density lipoprotein and decreased high-density lipoprotein, Lipids 46 (2011) 953–960. https://doi.org/10.1007/s11745-011-3580-y.  [47] M.S. Kostapanos, A.T. Spyrou, **C.C. Tellis,** I.F. Gazi, A.D. Tselepis, M. Elisaf, E.N. Liberopoulos, Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress, Lipids 46 (2011) 341–348. https://doi.org/10.1007/s11745-011-3539-z.  [48] A.D. Tselepis, M.E. Tsoumani, K.I. Kalantzi, A.A. Dimitriou, **C.C. Tellis**, I.A. Goudevenos, Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy, Journal of Thrombosis and Haemostasis 9 (2011) 2371–2378. https://doi.org/10.1111/j.1538-7836.2011.04541.x.  [49] K.E. Tsimogiannis, **C.C. Tellis\***, A.D. Tselepis, G. Pappas-Gogos, M.S. Bakola, E.C. Tsimoyiannis, C.E. Simopoulos, M. Pitiakoudis, α-defensins and hsCRP levels in inflammatory response of standard and laparoendoscopic single-site cholecystectomy, Surg Endosc 26 (2012) 627–631. https://doi.org/10.1007/s00464-011-1921-9.  [50] K.E. Tsimogiannis, **K. Telis\***, A. Tselepis, G.K. Pappas-Gogos, E.C. Tsimoyiannis, G. Basdanis, Α-Defensin Expression of Inflammatory Response in Open and Laparoscopic Colectomy for Colorectal Cancer, World J Surg 35 (2011) 1911–1917. https://doi.org/10.1007/s00268-011-1140-5.  [51] G.A. Christou, **C.C. Tellis**\*, M.S. Elisaf, A.D. Tselepis, D.N. Kiortsis, The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment, Angiology 63 (2012) 67–75. https://doi.org/10.1177/0003319711407628.  [52] G.A. Christou, **C.C. Tellis\***, M.S. Elisaf, A.D. Tselepis, D.N. Kiortsis, High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment, Hormones 11 (2012) 178–188. https://doi.org/10.14310/horm.2002.1345.  [53] **C.C. Tellis,** A.D. Tselepis, Τhe role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma, Biochim Biophys Acta Mol Cell Biol Lipids 1791 (2009) 327–338. https://doi.org/10.1016/j.bbalip.2009.02.015.  [54] F. Apostolou, I.F. Gazi, A. Kostoula, **C.C. Tellis,** A.D. Tselepis, M. Elisaf, E.N. Liberopoulos, Persistence of an atherogenic lipid profile after treatment of acute infection with brucella, J Lipid Res 50 (2009) 2532–2539. https://doi.org/10.1194/jlr.P900063-JLR200.  [55] A.D. Tselepis, D.B. Panagiotakos, C. Pitsavos, **C.C. Tellis**, C. Chrysohoou, C. Stefanadis, Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: The ATTICA Study, Atherosclerosis 206 (2009) 303–308. https://doi.org/10.1016/j.atherosclerosis.2009.02.016.  [56] F. Apostolou, I.F. Gazi, K. Lagos, **C.C. Tellis,** A.D. Tselepis, E.N. Liberopoulos, M. Elisaf, Acute infection with Epstein-Barr virus is associated with atherogenic lipid changes, Atherosclerosis 212 (2010) 607–613. https://doi.org/10.1016/j.atherosclerosis.2010.06.006.  [57] V. Tsimihodimos, I. Gazi, T. Filippatos, M. Kostapanos, K. Lagos, C. Kostara, **C.C. Tellis**, M. Elisaf, A.D. Tselepis, Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia, Atherosclerosis 208 (2010) 506–511. https://doi.org/10.1016/j.atherosclerosis.2009.07.038.  [58] A.D. Tselepis, G. Hahalis, **C.C. Tellis,** E.C. Papavasiliou, P.T. Mylona, A. Kourakli, D.C. Alexopoulos, Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β-thalassemia, J Lipid Res 51 (2010) 3331–3341. https://doi.org/10.1194/jlr.M007229.  [59] M. Florentin, E.N. Liberopoulos, **C.C. Tellis**, C.S. Derdemezis, M. Elisaf, A. Tselepis, Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: A pilot study, Angiology 61 (2010) 365–371. https://doi.org/10.1177/0003319709352488.  [60] C. V. Rizos, E.N. Liberopoulos, **C.C. Tellis**, M. Florentin, M.S. Elisaf, A.D. Tselepis, Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A2, Metab Syndr Relat Disord 9 (2011) 217–223. https://doi.org/10.1089/met.2010.0120.  [61] A. Constantinides, M.N. Kerstens, B.D. Dikkeschei, L.J. van Pelt, **C.C. Tellis**, A.D. Tselepis, R.P.F. Dullaart, Plasma Lp-PLA2 mass and apoB-lipoproteins that carry Lp-PLA2 decrease after sodium, Eur J Clin Invest 42 (2012) 1235–1243. https://doi.org/10.1111/j.1365-2362.2012.02719.x.  [62] V.D. Roussa, E.M. Stathopoulou, N.D. Papamichael, C. V. Englezopoulos, K.I. Rousouli, P. Trypou, V. Moussis, **C.C. Tellis**, C.S. Katsouras, V. Tsikaris, A.D. Tselepis, L.K. Michalis, A highly constrained cyclic (S,S)-CDC- peptide is a potent inhibitor of carotid artery thrombosis in rabbits, Platelets 22 (2011) 361–370. https://doi.org/10.3109/09537104.2010.531795.  [63] M.I. Darvari, M.P. Petraki, **C. Tellis,** K. Harilogis, A.D. Tselepis, M. Sakarellos-Daitsiotis, Apolipoprotein A-I peptide models as probes to formulate potential inhibitors of the low-density lipoprotein oxidation, Journal of Peptide Science 17 (2011) 720–725. https://doi.org/10.1002/psc.1391.  [64] G. Nakos, J. Pneumatikos, I. Tsangaris, **C. Tellis,** M. Lekka, Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema, Am J Respir Crit Care Med 155 (1997) 945–951. https://doi.org/10.1164/ajrccm.155.3.9117030.  [65] D. Pantazi, E. Drougas, B. Loppinet, **C. Tellis,** A.M. Kosmas, M.E. Lekka, Hydrolysis by phospholipase D of phospholipids in solution state or adsorbed on a silica matrix, Chem Phys Lipids 139 (2006) 20–31. https://doi.org/10.1016/j.chemphyslip.2005.09.005.  [66] **C. Tellis,** D. Pantazi, E. Ioachim, V. Galani, M.E. Lekka, Localization of an alkyl-acetyl-glycerol-CDP-choline: Cholinephosphotransferase activity in submitochondrial fractions of Tetrahymena pyriformis, Eur J Cell Biol 82 (2003) 573–578. https://doi.org/10.1078/0171-9335-00343.  [67] **C. Tellis,** M.E. Lekka, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphate:phosphohydrolase activity in Tetrahymena pyriformis, Journal of Eukaryotic Microbiology 47 (2000) 122–128. https://doi.org/10.1111/j.1550-7408.2000.tb00021.x.  [68] **C. Tellis**, D.C. Tsoukatos, M.E. Lekka, Isolation, chemical characterization, and subcellular distribution of 1-O-alkyl-2-acetyl-sn-glycerol in Tetrahymena pyriformis cells, J Biochem 119 (1996) 823–827. https://doi.org/10.1093/oxfordjournals.jbchem.a021314. | |